Jade Biosciences (JBIO) Capital Expenditures (2021 - 2025)
Jade Biosciences' (JBIO) quarterly Capital Expenditures came in at -$155000.0 in Q4 2025, down 168.58% YoY from $226000.0 in Q4 2024, and down 155.16% on a QoQ basis from $281000.0 in Q3 2025.
Jade Biosciences (JBIO) Capital Expenditures (2021 - 2025) Analysis & Trends
Jade Biosciences (JBIO) has 5 years of Capital Expenditures data on file, last reported at -$155000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 168.58% year-over-year to -$155000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $38000.0 (up 106.75% YoY) and the FY2025 annual result came in at $38000.0, up 106.75% from the prior year.
- Capital Expenditures fell to -$155000.0 in Q4 2025, from $281000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q3 2024 to a low of -$2.5 million in Q2 2024.
- A 5-year average of $77789.5 and a median of $28000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 13030.77% — and 2024, when it plunged 15775.0%.
- Tracing JBIO's Capital Expenditures over 5 years: stood at -$13000.0 in 2021, then jumped by 13030.77% to $1.7 million in 2022, then slumped by 98.1% to $32000.0 in 2023, then surged by 606.25% to $226000.0 in 2024, then slumped by 168.58% to -$155000.0 in 2025.
- The last three Capital Expenditures figures came in at -$155000.0 (Q4 2025), $281000.0 (Q3 2025), and -$28000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -155,000.00 |
| Dec 31, 2025 | -155,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Sep 30, 2025 | 281,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Jun 30, 2025 | -28,000.00 |
| Mar 31, 2025 | -60,000.00 |
| Mar 31, 2025 | -60,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Dec 31, 2024 | 226,000.00 |
| Sep 30, 2024 | 1.72 Mn |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2,000.00 |
| Mar 31, 2024 | -2,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Sep 30, 2023 | 32,000.00 |